Trial Information
Protocol for Radiofrequency Ablation of Pulmonary Neoplasms
Inclusion Criteria:
The patients enrolled in this study should be judged to have
sufficient survival to benefit from control of local disease and include at least one of
the following:
1. unresectable primary or metastatic lung tumors
2. may benefit from multiple modalities of therapy
3. chemotherapeutic or radiation oncologic options have been exhausted
Exclusion Criteria:
1. co-existing morbidities that preclude the use of surgery
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Principal Investigator
Marshall T. Schreeder, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Comprehensive Cancer Institute
Authority:
United States: Institutional Review Board
Study ID:
CCI LUN 02
NCT ID:
NCT00232128
Start Date:
June 2003
Completion Date:
Related Keywords:
- Pulmonary Neoplasms
- Neoplasms
- Lung Neoplasms
Name | Location |
Comprehensive Cancer Institute |
Huntsville, Alabama 35801 |